Real‐world study of lazertinib as second‐line or greater treatment in advanced non‐small cell lung cancer

Real‐world study of lazertinib as second‐line or greater treatment in advanced non‐small cell lung cancer

Abstract Background Lazertinib is an oral, third‐generation EGFR‐TKI, which specifically targets the EGFR T790M mutation along with activating mutations Ex19del and L858R. More real‐world data are needed to evaluate its efficacy and safety in treating locally advanced and metastatic non‐small cell l...

Full description

Bibliographic Details
Main Authors: Jeong Uk Lim, Kyuhwan Kim, Kyu Yean Kim, Hye Seon Kang, Ah. Young Shin, Chang Dong Yeo, Sung Kyoung Kim, Chan Kwon Park, Sang Haak Lee, Seung Joon Kim
Format: Article
Language:English
Published: Wiley 2024-07-01
Series:Thoracic Cancer
Subjects:
EGFR mutation
lazertinib
non‐small cell lung cancer
targeted therapy
Online Access:https://doi.org/10.1111/1759-7714.15337

Internet

https://doi.org/10.1111/1759-7714.15337

Similar Items